Active
Atlas Opportunity Score 65/100
Verified September 10, 2026
National Cancer Institute (NCI)
NCI SBIR Innovative Concept Award — 75N98026R00109
NCI Phase I SBIR contract offering $300,000 for high-risk, high-reward technologies in pediatric and rare cancers. Proposals are due September 21, 2026 at 5:00 PM ET. N9+ fit is conditional on a defensible cancer-specific R&D objective.
Required next actionRun a rapid cancer-specific technical screen before any direct pursuit. Advance only if N9+ or another Dr. Miltie capability can support a genuinely innovative pediatric- or rare-cancer research, detection, treatment, or care objective and all SBIR contract eligibility, registration, personnel, and submission requirements can be satisfied.